News Category
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and an FDA...
Med-X is expanding its Nature-Cide natural pest-control brand and has obtained OMRI certification for key products as it prepares for a planned Nasdaq...
Telomir Pharmaceuticals' Telomir-Zn inhibits growth in human and canine osteosarcoma cell lines at low concentrations, supporting further studies that...
Quantum BioPharma has received FDA clearance for its Investigational New Drug application for Lucid-MS, allowing the company to initiate a Phase 2 tri...
GeoVax has entered an agreement with CEPI to use its Centralised Laboratory Network for independent testing in the GEO-MVA Phase 3 trial, a move that ...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNA gene therapy can restore full-length dystrophin and im...
Creative Biolabs has broadened its lipid-based delivery development services to help researchers address stability, targeting, and controlled release ...
Creative Biolabs has broadened its single-cell RNA sequencing, single-nucleus RNA sequencing, and single-cell multi-omics services to help researchers...
A new review reveals that the tumor microenvironment actively reprograms natural killer cells into distinct subsets, offering a framework for more pre...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin cancer therapy, highlighting th...
Regentis Biomaterials reported progress in its Phase III GelrinC trial and European regulatory approval for a manufacturing process that boosts yield ...
Quantum BioPharma receives FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug that aims to protect and rebu...
TransCode Therapeutics has appointed John Tattory as interim CFO following the immediate retirement of Tom Fitzgerald, a change that could impact the ...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer underscores its commitment to advancing its BiTAC® technology and onco...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis therapy that targets demyelinat...
Quantum BioPharma's FDA clearance to launch a phase 2 trial of Lucid-MS signals a potential paradigm shift in multiple sclerosis treatment from immune...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and r...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the company's prog...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets PNKP with a dual selectivity approach, and its potential to ad...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor that targets demyelination directly, has received FDA clearance to begin a ...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving peak pressures of 100,000 atmospheres and attracting new equ...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing therapies to overcome cancer drug...
Nutriband's CEO will attend the inaugural Nasdaq LaB Biotech Summit, spotlighting the company's AVERSA technology aimed at preventing opioid abuse, wh...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores the importance of its nose-to-brain drug delivery platform, with ne...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a novel myelin repair candidate, marks a pivotal step in potentially changing the M...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 tria...
Helus Pharma's CEO participation in a key industry conference underscores the company's advancing clinical trials for novel depression and anxiety tre...
GeoVax supports the new global mpox vaccine stockpile initiative, emphasizing the need for diversified supply and highlighting its GEO-MVA candidate's...
Voyageur Pharmaceuticals has received a USD $1 million milestone payment from Bayer after submitting an approved feasibility work plan, advancing its ...
Greenland Mines announces Q4 biotech spin-off, Nasdaq compliance, and acquisition of Sarfartoq rare earths project, signaling a strategic pivot toward...
VERAXA Biotech's appointment of Raju Willener as CFO brings seasoned financial leadership to support its capital strategy and advance its proprietary ...
Scinai Immunotherapeutics strategically refocuses its R&D portfolio on its NanoAb platform and CDMO business after terminating its PC111 license with ...
Onco-Innovations Ltd. advances its oncology pipeline by building manufacturing capabilities, IND-enabling activities, and securing funding, positionin...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class remyelinating agent, could address the unmet need in MS by potenti...
OS Animal Health's participation in the Moody Capital conference highlights its progress in developing OST-HER2 for canine osteosarcoma, underscoring ...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a pivotal step toward a treatment that could protect and repair myelin in M...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Democratic Republic of Congo, marking a potential advancement in ...
Greenland Mines advances its rare earths strategy with Nasdaq compliance, Sarfartoq acquisition, and a planned biotech spin-off, positioning for signi...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS marks a critical step toward a first-in-class multiple sclerosis therapy that t...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS marks a pivotal step toward a targeted therapy for multiple sclerosis, potentia...
Quantum BioPharma's FDA clearance to initiate a Phase 2 trial of Lucid-MS marks a significant step toward a novel treatment for multiple sclerosis tha...
The LGL Group's participation in the Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference underscores its dual-platform strateg...
Interlink Electronics' participation in the Moody Capital Solutions conference underscores its strategic growth in sensors and printed electronics acr...
The 2026 Disruptive Growth & Life Sciences Conference by Moody Capital Solutions gathers two booming small-cap sectors, life sciences and AI-driven en...
Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer to lead commercial efforts for TONMYA and migraine products, signaling strat...
AcroMeta Group Limited has signed a non-binding term sheet to acquire a strategic stake in Macro-ATCLS Pte. Ltd. and secure an exclusive license to de...
Onco-Innovations' ONC010 progresses through preclinical development, achieving 99.3% purity and planning a First-in-Human study in Australia, highligh...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to bolster its capital strategy and advance...
